Journal article icon

Journal article

Unique genetic signatures in HIV-1 subtype A1 and A1D recombinant envelope glycoprotein distinguish contemporary transmitted/founder viruses from historical strains in East Africa

Abstract:
INTRODUCTION: The envelope glycoprotein (Env) of HIV-1 Transmitted/Founder (T/F) viruses in subtypes B and C carries distinct genetic signatures that enhance transmission fitness, augment infectivity and immune evasion. However, there is limited data on such signatures in T/F subtypes A1, D and A1D recombinants that predominate East Africa's HIV epidemic. METHODS: We used phylogenetically corrected approaches to detect distinct genetic signatures by comparing 44 contemporary HIV-1 T/F Envs with 229 historical Envs of the same subtype in East Africa. RESULTS AND DISCUSSION: Subtype analysis based on the full-length Env gene of contemporary T/F viruses revealed a high proportion of subtype A1, followed by A1D recombinants, and fewer subtype D. Signature analysis revealed that the contemporary subtype A1 T/Fs were more likely to select distinct amino acids, including M22 in the signal peptide, R82 in gp120, A172 in the V2 loop, E230 in the glycosite 230, K275 in the D loop, Y317 in the V3 loop, K476 and N477 in the CD4 contact site, when compared with the historical Envs (q-value < 0.2). Conversely, the contemporary subtype A1 T/F Envs were less likely to carry the amino acids Q432 in the CD4 contact site, and the L784 signature within the LLP-2 (q-value < 0.2). The A1D recombinant T/Fs were more likely to select the D620 in the C-helix, but under selected the L34 in gp120, P299 in the V3 loop and Y643 in the Heptad repeat-2, compared to the historical Envs (q-value < 0.2). The distinct signature sites reported in this study may contribute to the successful establishment of acute infection as well as the persistence of long-term infection. Therefore, effective therapeutics and vaccines may target these distinct amino acid signatures especially for the East African region as it may be necessary to employ subtype-specific vaccines according to the subtype distribution
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Authors

More by this author
Role:
Author
ORCID:
0000-0001-5075-0756
More by this author
Role:
Author
ORCID:
0000-0002-0726-1276
More by this author
Role:
Author
ORCID:
0000-0002-5962-151X
More by this author
Role:
Author
ORCID:
0000-0001-5068-1746


Publisher:
Frontiers Media
Journal:
Frontiers in Microbiology More from this journal
Volume:
16
Pages:
1632581-1632581
Publication date:
2025-08-04
DOI:
EISSN:
1664-302X
ISSN:
1664-302X


Language:
English
Keywords:
Pubs id:
2279305
Local pid:
pubs:2279305
Source identifiers:
W4412882140
Deposit date:
2026-08-02
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP